Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589615 | 0.94 | ALDH1A1 (0.32) | PSMB8PSMB5ALDH1A1TP53CYP3A4 | |
| SCHEMBL5223027 | 0.86 | PSMB8 (0.31) | PSMB8PSMB5 | |
| SCHEMBL2593469 | 0.84 | TSHR (0.37) | PSMB8PSMB5MAPK1SMN1; SMN2 | |
| SCHEMBL22777675 | 0.82 | SMN1; SMN2 (0.36) | PSMB8PSMB5SMN1; SMN2 | |
| SCHEMBL34383 | 0.82 | SMN1; SMN2 (0.36) | PSMB8PSMB5SMN1; SMN2 | |
| SCHEMBL7954092 | 0.81 | DGKA (0.40) | PSMB8PSMB5ALDH1A1MAPK1SMN1; SMN2 | |
| Ethylene Glycol SCHEMBL6523939 | 0.81 | PSMB8 (0.34) | PSMB8PSMB5SMN1; SMN2 | |
| SCHEMBL13606697 | 0.81 | MAPT (0.32) | MAPK1 | |
| SCHEMBL29945244 | 0.81 | SMN1; SMN2 (0.36) | PSMB8PSMB5SMN1; SMN2 | |
| SCHEMBL310052 | 0.80 | MGLL (0.37) | PSMB8PSMB5MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | THERAGENICS CORPORATION | 2019-08-29 | — | — | US | claimed |
| US-10189773-B2 | In-vivo gelling pharmaceutical pre-formulation | MEDICUS BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | claimed |
| EP-2846847-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | Medicus Biosciences LLC (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | claimed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | claimed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | claimed |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | AQUARIAN CREDIT FUNDING LLC | 2023-07-13 | — | — | US | disclosed |
| EP-2968680-B1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | C P MEDICAL CORP (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | AQUARIAN CREDIT FUNDING LLC | 2023-03-07 | — | — | US | disclosed |
| US-20210322785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | THERAGENICS CORPORATION | 2021-10-21 | — | — | US | disclosed |
| EP-3893785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | C.P. Medical Corporation (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11083821-B2 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | C.P. MEDICAL CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200316249-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | AQUARIAN CREDIT FUNDING LLC | 2020-10-08 | — | — | US | disclosed |
| WO-2014153004-A1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | MEDICUS BIOSCIENCES LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140271528-A1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | MEDICUS BIOSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140248231-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES LLC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2708224-A1 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | Medicus Biosciences LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189773-B2 | In-vivo gelling pharmaceutical pre-formulation | FURIN, ARFGAP1, MGST1 | PSMB8 1695/4885PSMB5 2319/4885ALDH1A1 84/4885 |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | ALDH1A2, RB1, UACA | PSMB8 2250/4885PSMB5 2255/4885ALDH1A1 297/4885 |
| US-11083821-B2 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | HMGB1, HDGF, CRYAA | PSMB8 1033/4885PSMB5 2433/4885ALDH1A1 661/4885 |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | ALDH1A2, RB1, UACA | PSMB8 2250/4885PSMB5 2255/4885ALDH1A1 297/4885 |
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | PSMB8 1715/4885PSMB5 2559/4885ALDH1A1 113/4885 |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | PSMB8 1695/4885PSMB5 2319/4885ALDH1A1 84/4885 |
| US-20200316249-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | ALDH1A2, RB1, UACA | PSMB8 2250/4885PSMB5 2255/4885ALDH1A1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.